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OBJECTIVE — There is growing evidence that osteocalcin, an osteoblast-derived protein
locally acting on bone formation, can increase insulin secretion as well as insulin sensitivity and
thus prevent the development of obesity and diabetes in experimental animals. In humans,
osteocalcin has been reported to be decreased in patients with type 2 diabetes. Because gesta-
tional diabetes mellitus (GDM) can serve as a model of pre–type 2 diabetes, the aim of this study
was to investigate osteocalcin in GDM.
RESEARCH DESIGN AND METHODS — Osteocalcin measurement and an oral glu-
cose tolerance test were performed in 78 pregnant women (26 women had GDM and 52 women
had normal glucose tolerance [NGT] during pregnancy; women were matched for age and BMI)
and in 34 women postpartum.
RESULTS — During pregnancy osteocalcin was signiﬁcantly higher in the women with GDM
than in the women with NGT (15.6  6.4 vs. 12.6  4.0 ng/ml; P  0.015), whereas no
difference was observed between the two groups at 12 weeks postpartum (36.2  10.2 vs.
36.2  13.0 ng/ml), when osteocalcin was found to be increased compared with the level in the
pregnant state in all women (145  102% in GDM vs. 187  119% in NGT; P  0.0001).
Moreover, osteocalcin showed a signiﬁcant correlation with basal and total insulin secretion in
the whole study group (R  0.3, P  0.01).
CONCLUSIONS — In GDM osteocalcin was higher and thus less restrained than in women
with NGT during pregnancy and furthermore correlated with insulin secretion parameters.
Therefore, it could be hypothesized that osteocalcin can enhance insulin secretion in insulin-
resistant states; alternatively an effect of hyperinsulinemia on osteocalcin secretion cannot be
excluded.
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E
vidence is growing regarding the re-
ciprocal interaction between bone
and energy metabolism (1). The
ﬁndings that adipose tissue via leptin can
regulate bone metabolism (2) and that in-
sulin, as an anabolic hormone, inﬂuences
bone metabolism via IGF-1 (3,4) raised
theideathatboneinturncouldalsoaffect
energy metabolism. Osteocalcin, an os-
teoblast-derived protein acting locally on
bone formation, is suspected to be in-
volvedintheregulationofglucoseandfat
metabolism. Because animal models
showed that mice lacking osteocalcin dis-
play insulin resistance and obesity, bone
became a focus of interest concerning en-
docrine action as did adipose tissue when
adipocytokinesweredetected.Ithasbeen
demonstrated that osteocalcin can stimu-
late insulin secretion, acting directly on
proliferation and secretion of the pancre-
atic -cells. Osteocalcin might act via an
endocrine pathway, and, indeed, osteo-
calcin has been reported to exert several
hormone-speciﬁc features. Furthermore,
it has been shown that osteocalcin can in-
crease insulin sensitivity, probably by in-
ducing the expression of adiponectin in
adipocytes. Besides, mice lacking the Esp
gene that encodes for a receptor-like pro-
tein called OST-PTP, which is thought to
inﬂuence the bioactivity of osteocalcin,
show increased energy expenditure and
decreased levels of triglycerides and are
protected from diet-induced obesity and
diabetes (5).
In humans, osteocalcin has been re-
ported to be decreased in patients with
type 2 diabetes (6), negatively correlated
with fasting plasma glucose, A1C, insulin
resistance (assessed by homeostasis
model assessment of insulin resistance),
high-sensitivity C-reactive protein (hs-
CRP), and BMI and increased with im-
proved glycemic control (7,8). Moderate
weight loss and regular exercise have also
been found to increase osteocalcin con-
centrations, partly by direct effects of ex-
erciseonboneremodelingandpartlybya
reduction in visceral fat (9). Further-
more, weight loss after bariatric surgery
has been reported to be associated with
a signiﬁcant increase in osteocalcin
(10). These ﬁndings again emphasize the
connection between osteocalcin and sub-
strate metabolism.
Because gestational diabetes mellitus
(GDM), deﬁned as glucose intolerance
ﬁrst detected during pregnancy (11),
serves as a model to study the early
changes in the development of insulin re-
sistance and type 2 diabetes, interest in
theactionandregulationofosteocalcinin
this entity, which affects about 10% of
pregnant women in the middle European
population, has increased. Besides pro-
nounced insulin resistance compared
with that in women with normal glucose
tolerance (NGT) during pregnancy (12),
pancreatic -cell dysfunction has been
described as the main metabolic charac-
teristicinwomenwithGDM(13).Despite
increased insulin release, women with
GDM fail to cope with the increased insu-
lin demand during the physiological
insulin resistance of late pregnancy, re-
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women with GDM regain NGT after de-
liverybuthavealife-longincreasedriskof
developing type 2 diabetes, especially
within the ﬁrst 10 years after delivery
(14). Therefore, the aim of this study was
to investigate, for the ﬁrst time, osteocal-
cin and its associations with glucose me-
tabolism in GDM both during pregnancy
and after delivery.
RESEARCH DESIGN AND
METHODS— The study was per-
formed as a case-control study at the out-
patient clinic of the Department of
Internal Medicine III, Division of Endo-
crinology and Metabolism of the Medical
University of Vienna. Healthy pregnant
women, who were referred from the de-
partment of obstetrics and gynecology to
the outpatient clinic for routine glucose
tolerance testing between the 24th and
28th gestational weeks, were invited to
take part in this investigation. None of
these women had a high risk for GDM
(e.g., a history of GDM or obstetric com-
plications in a previous pregnancy, any
history of impaired glucose tolerance, or
signsoffetalmacrosomia),and,therefore,
no prior glucose tolerance testing was
performed during the respective preg-
nancy. Women who gave informed con-
sent underwent a 2-h oral glucose
tolerance test (OGTT) and fasting plasma
sampling for the measurement of osteo-
calcin, A1C, hs-CRP, and lipid proﬁle.
We used the American Diabetes Associa-
tion criteria for the deﬁnition of GDM:
fasting plasma glucose values 95 mg/dl,
1-h postload 75-g glucose value 180
mg/dl, or 2-h postload glucose value
155 mg/dl. GDM was diagnosed when
one value was pathological. All women
with GDM received dietary counseling
and were requested to measure their
blood glucose levels four times daily. If
the aim to achieve blood glucose levels
90 mg/dl at fasting and 140 mg/dl 1 h
aftermealcouldnotbeachievedbynutri-
tion therapy, additional insulin therapy
was started.
Data from 26 women with GDM and
52 women with NGT during pregnancy,
matched for age and BMI in a 1:2 ratio,
wereanalyzed.Allwomenwereinvitedto
undergo reexamination during late preg-
nancy and 10–12 weeks after delivery.
OGTT
After women had fasted overnight for at
least 12 h, a catheter was placed into an
antecubital vein, and blood samples for
the measurement of glucose, insulin, and
C-peptide were taken at baseline as well
as at 30, 60, 90, and 120 min after inges-
tion of 75 g glucose in H2O solution.
Plasma metabolites
N-MIDosteocalcinwasmeasuredwithan
electrochemiluminescent immunoassay
(Roche Diagnostics, Mannheim, Ger-
many)usingaRocheModular170immu-
noassay analyzer. Interassay coefﬁcients
of variation were 4.2–4.5% and 85 and
169 ng/ml, respectively. Glucose, insulin,
C-peptide, C-reactive protein (CRP), hs-
CRP, A1C, total cholesterol, LDL choles-
terol, and HDL cholesterol were measured
with standard kits available in our central
laboratory.
Data analysis
The kinetics of glucose, insulin, and C-
peptide during the OGTT were analyzed
by quantitative methods to obtain meta-
bolic parameters, such as insulin sensitiv-
itythroughoralglucoseinsulinsensitivity
(OGIS), which describes glucose clear-
anceperunitchangeofinsulinconcentra-
tion (15). Total insulin secretion (TIS)
from C-peptide, its suprabasal compo-
nent (dynamic TIS), and hepatic insulin
extraction (HIE) were obtained with a
mathematical model of insulin/C-peptide
interactions (16,17). -Cell function was
described as the ability of the -cell to
adapt insulin secretion to the prevailing
insulin resistance and was quantiﬁed by
the products: OGIS  dynamic AUC in-
sulin (termed disposition index) and
OGIS  dynamic TIS (termed adaptation
index), where AUC is the area under the
insulin concentration curve during the
whole test.
Statistical analysis
Comparisons of quantitative variables
among groups were performed using
ANOVA. Associations between continu-
ousvariablesaredescribedbythePearson
correlation coefﬁcient. Multiple regres-
sion models were used to assess the in-
ﬂuence of osteocalcin on metabolic
parameters, taking into account poten-
tial factors associated with this variable
such as BMI and age. Levels of statistical
signiﬁcance were set at P  0.05.
RESULTS
Osteocalcin and metabolic
parameters in pregnancy
During pregnancy, plasma concentrations
of osteocalcin were signiﬁcantly higher in
women with GDM compared with women
with NGT (Table 1). Furthermore, GDM
showed signiﬁcantly elevated levels of glu-
coseatalltimepointsduringanOGTT(Fig.
1A). TIS (Fig. 1B), the area under the curve
ofinsulin(AUC_insulin)andtheareaunder
Table 1—Baseline characteristics and metabolic parameters in women with GDM and NGT
during pregnancy (24th–28th gestational weeks)
GDM NGT P
BMI (kg/m²) 27.8  4.8 28.0  5.1 NS
Age (years) 33  63 2  6N S
Parity 1.2  1.26 0.75  1.17 NS
Systolic blood pressure (mmHg) 110.4  12.2 110.4  9.6 NS
Diastolic blood pressure (mmHg) 68.1  6.2 69.0  7.6 NS
Thyroid-stimulating hormone (U/ml) 1.7  1.0 1.8  1.0 NS
Free triiodothyronine (pg/ml) 2.85  0.37 2.78  0.32 NS
Free thyroxineT4 (ng/dl) 0.94  0.14 0.96  0.15 NS
Osteocalcin (ng/ml) 15.6  6.4 12.6  4.0 0.0146
Triglycerides (mg/dl) 199  70 183  64 NS
Total cholesterol (mg/dl) 265.1  44.3 267.3  43.0 NS
HDL cholesterol (mg/dl) 71.0  15.5 76.8  14.2 NS
LDL cholesterol (mg/dl) 154.3  39.5 154.4  35.2 NS
A1C (%) 4.98  0.39 4.72  0.48 0.03
hs-CRP (mg/dl) 1.26  3.18 0.53  0.46 NS
Fasting glucose (mg/dl) 85  97 8  5 0.0001
Basal insulin secretion (pmol   l
1   min
1) 40.54  16.59 33.72  12.85 NS
Disposition index (nmol/m
3) 22.24  8.22 17.56  7.18 0.02
AUC_glucose (mmol   l
1   min
1) 1.04  0.1 0.79  0.1 0.0001
AUC_insulin (nmol   l
1   min
1) 68.4  27.5 48.4  23.6 0.002
AUC_C-peptide (nmol   l
1   min
1) 393.9  111.4 318.4  102.7 0.006
Osteocalcin and insulin secretion in GDM
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were signiﬁcantly increased in women with
GDM compared with women with NGT
(Table 1). Insulin sensitivity (OGIS) was
signiﬁcantly decreased in women with
GDM compared with women with NGT
(Fig. 1C). The disposition index was signif-
icantly increased in women with GDM (Ta-
ble 1), further indicating good secretory
compensation. No differences were de-
tected between women with GDM and
NGTforCRP,hs-CRP,andlipidproﬁle(Ta-
ble 1).
Correlation analysis
Osteocalcin was positively correlated
with areas under the curve of glucose, in-
sulin (Fig. 2A), and C-peptide during
pregnancyinthewholestudygroup.Fur-
thermore, osteocalcin was signiﬁcantly
correlated with insulin secretion parame-
ters (Table 2) and especially with the dis-
position index (Fig. 2B) and the
adaptation index. Conversely, hepatic in-
sulin extraction was inversely correlated
withosteocalcin(Table2).Nocorrelation
was found between osteocalcin and A1C.
Multipleregressionmodelswithosteocal-
cin as the dependent variable and age,
BMI, and group as quantitative variables
showed that only the group (GDM or
NGT) had a signiﬁcant inﬂuence on os-
teocalcin concentrations.
Longitudinal observation
Twelve women with GDM could also be
studied between the 33rd and 38th gesta-
tional weeks. Osteocalcin (22.7  9 ng/
ml;39.5%;P0.009)wassigniﬁcantly
increased compared with that at the ﬁrst
Figure 2—Correlation analysis during pregnancy in the whole study group: osteocalcin corre-
lates positively with parameters of insulin secretion such as the AUC of insulin (A) and the
disposition index (B).
Figure 1—Comparison of dynamic AUC glu-
cose (A), TIS (B), and insulin sensitivity
(OGIS) (C) during pregnancy between women
with GDM and women with NGT.
Table 2—Correlation analysis: correlations
between osteocalcin and parameters of glu-
cose metabolism (Spearman correlation coef-
ﬁcient) during pregnancy in the whole study
group
Osteocalcin
RP
TIS 0.33 0.005
Dynamic TIS 0.3 0.008
Basal insulin secretion 0.23 0.05
AUC_C-peptide 0.3 0.009
AUC_glucose 0.3 0.007
HIE 0.24 0.04
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again did not relate to glycemic control
(A1C and 	A1C); furthermore, osteocal-
cin was not different between those
women with GDM receiving nutrition
therapy only and those who were treated
with diet and insulin.
Postpartum reexamination
From 78 women investigated during
pregnancy,34(17withGDMand17with
NGT) underwent postpartum fasting
plasma sampling, and from these women
17 (10 with GDM and 7 with NGT) also
agreed to undergo an OGTT for glucose
tolerance reevaluation. At 10–12 weeks
postpartum all of the women with prior
GDM analyzed by OGTT had already re-
gained NGT. There was no difference be-
tween women with prior GDM and
women with prior NGT concerning met-
abolic parameters except in the dynamic
AUC_insulin during the OGTT, which
was marginally increased in women with
prior GDM (35.07  14.22 vs. 21.05 
10.91 nmol   l
1   min
1; P  0.045).
Insulin sensitivity (OGIS: prior GDM
42156ml min
1 m
1vs.priorNGT
460  54 ml   min
1   m
1) was not dif-
ferent between the groups at the postpar-
tum visit.
Osteocalcin did not differ between
women with prior GDM and prior NGT
(36.2  10.2 vs. 36.2  13.0 ng/ml) at
the postpartum visit but was signiﬁcantly
increased compared with pregnancy val-
ues (P  0.0001). No correlations were
foundbetweenosteocalcinandinsulinse-
cretion or AUC of glucose, whereas fast-
ing glucose was inversely correlated with
osteocalcin, but this correlation did not
reach statistical signiﬁcance (R  0.44,
P  0.07).
CONCLUSIONS — This is the ﬁrst
time that osteocalcin was investigated in
GDM, an entity that is characterized by
hyperglycemia due to the failure of the
pancreatic -cells to cope with increased
insulin demand during the pronounced
increase of the physiological insulin resis-
tance period of late pregnancy (13). Fur-
thermore, women with GDM have a high
risk for later development of type 2 dia-
betes(14).Previously,osteocalcinwasre-
ported to be decreased in patients with
type 2 diabetes (6). In our study, osteo-
calcin was less restrained in women with
GDM than in women with NGT between
the 24th and 28th gestational weeks. At
the postpartum visit, we found no differ-
ences in osteocalcin plasma concentra-
tions between the two groups. In both
groups osteocalcin was signiﬁcantly nor-
malized 12 weeks after delivery, in accor-
dance with ﬁndings in previous studies,
which showed that osteocalcin levels de-
cline in early pregnancy, start to increase
in the third trimester until delivery, and
peak during lactation (18–20). There-
fore, our longitudinal observations are in
accordance with those in previous stud-
ies,showinganincreaseofosteocalcinbe-
tween the 24th and 28th and 33rd and
38th gestational weeks. The fact that os-
teocalcinwashigherinwomenwithGDM
than in women with NGT during preg-
nancy and was normalized postpartum
suggests that osteocalcin declines to a
smaller extent in women with GDM.
Recent ﬁndings in animal studies
have shown that osteocalcin can increase
insulinsecretionbyadirecteffectonpan-
creatic -cells (5). In our study group os-
teocalcin levels were positively correlated
withparametersofinsulinsecretion,such
as TIS, AUC_insulin, and AUC_C-
peptide.Thedispositionindex,whichde-
scribes the ability to increase insulin
secretion to cope with increased insulin
resistance and thus represents a parameter
of overall glucose tolerance, was positively
correlated with osteocalcin. Therefore, it
may be hypothesized that the curbed de-
cline of osteocalcin in GDM could act as a
compensatory mechanism to cope with
pancreatic -cell dysfunction in these
women. In turn, the higher levels of os-
teocalcin in GDM could also result from
increased insulin secretion in these
women. In this context insulin can exert
anabolic features on bone metabolism via
IGF-1 (3,4). Thus, increased insulin se-
cretion to cope with increased insulin re-
sistance could also inﬂuence bone
metabolism during pregnancy. In addi-
tion, because osteocalcin was inversely
correlatedwithhepaticinsulinextraction,
increased osteocalcin might be related to
decreasedinsulinclearance,furtheryield-
ing peripheral hyperinsulinemia during
an OGTT.
Because osteocalcin is decreased in
patients with overt type 2 diabetes, osteo-
calcin elevation in GDM to cope with in-
creased insulin demand could be seen as
an early adaptation mechanism for im-
paired glucose tolerance, which fails with
the onset of overt type 2 diabetes. Studies
by Lee et al. (5) showed that osteocalcin
can increase insulin sensitivity, assessed
by a speciﬁc test and a hyperinsulinemic-
euglycemic clamp in Esp
/ mice. In hu-
mans, we could not ﬁnd any association
between osteocalcin and insulin sensitiv-
ity (OGIS). Our ﬁndings that osteocalcin
levels were also positively correlated with
glucose concentrations during pregnancy
are not concordant with the ﬁndings in
animal studies in which osteocalcin was in-
versely correlated with hyperglycemia.
Osteocalcin is normally used as a
markerofboneformationandthusforthe
diagnosisandtreatmentmonitoringofos-
teoporosis (21). To exclude the possible
effects of age and BMI on osteocalcin
plasmaconcentrations,ourstudypopula-
tionwasmatchedforageandBMIina1:2
ratio, and multiple regression models
conﬁrmed that these variables did not in-
terfere with our results.
In a prior investigation in elderly pa-
tients,A1Candhs-CRPwerereportedtobe
inversely associated with osteocalcin (9);
however, our data could not conﬁrm these
ﬁndings in pregnant women with or with-
out GDM. Even our longitudinal observa-
tions in GDM did not show an association
between osteocalcin and glycemic control,
assessed by A1C. Furthermore, osteocalcin
was not different between those women
with GDM who were receiving nutrition
therapy only and those who were treated
with diet and insulin. However, we must
also point out that our longitudinally inves-
tigated group was quite small.
At 10–12 weeks postpartum, women
with prior GDM had already regained
NGT, and their metabolic parameters did
not differ from those of the women with
NGT,exceptthatdynamicAUCofinsulin
was higher, although marginally. This
ﬁnding can be interpreted as chronic hy-
perinsulinemia in women with prior
GDM because of increased insulin resis-
tance reported for women with prior
GDM. However, postpartum insulin sen-
sitivity was not different between the two
groups in our study population, which
can be ascribed to the smaller number of
postpartum participants and the fact that
both groups were well matched for the
degree of overweight.
Inbothgroupswefoundsigniﬁcantdif-
ferences between pregnancy and postpar-
tum values for all metabolic parameters
(OGIS, disposition index, AUC_insulin,
HIE, A1C, and osteocalcin). Considering
the ﬁndings that women with prior GDM
showed increased insulin secretion param-
eters compared with women with NGT
during pregnancy and a signiﬁcant decline
in glucose, insulin, and C-peptide levels
postpartum,weconcludethatinsulinsecre-
tion may be impaired in these women but
can still be transiently increased in periods
Osteocalcin and insulin secretion in GDM
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additional mechanisms that have yet not
been considered enhance hyperglycemia in
these women during pregnancy.
In summary, GDM is associated with
amilderdeclineinplasmaconcentrations
of osteocalcin during the 24th–28th ges-
tational weeks. In view of the positive as-
sociation of osteocalcin with insulin
secretion parameters, this could reﬂect a
compensatory mechanism in insulin-
resistant young women in periods of pro-
nounced insulin resistance such as late
pregnancy to cope with increased insulin
demand, which cannot be accomplished
because of a pancreatic -cell defect in
these women.
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